相关实验视频
Updated: Mar 6, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
13.4K
核AGO2加剧了心力衰竭,通过心肌基因生成保留了排气分数,从而导致心脏衰竭
Kunying Jin1,2, Yuyan Tang1,2, Jiabing Zhan1,2,3
1Department of Cardiology, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, Hubei, China.
European heart journal
|March 5, 2026
概括
高脂肪饮食会通过激活核2 (AGO2) 引发心力衰竭,从而保持喷射分数 (HFpEF). 这一途径将脂质和类毒性联系起来,为代谢HFpEF提供了新的治疗点.
科学领域:
- 心血管生物学 心血管生物学
- 分子代谢的分子代谢.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 高脂肪饮食 (HFD) 正在增加心力衰竭与保存喷射小部分 (HFpEF) 的发生率.
- 微RNAs (miRNAs) 调节心脏功能和脂质代谢.
- 亚细胞2 (AGO2) 在HFpEF中的作用尚不清楚.
研究的目的:
- 研究核AGO2在HFD诱导的HFpEF中的作用.
- 阐明连接HFD,AGO2和心脏功能障碍的分子机制.
- 确定代谢性HFpEF的潜在治疗点.
主要方法:
- 使用复合腺相关病毒 (血清型9) 用于核AGO2操纵.
- 在心脏功能评估中使用心声回声仪,导管心力计和蛋白质组学.
- 进行了分子测定,包括ChIP, luciferase,西式涂抹和海马测定.
主要成果:
- 核AGO2倒置改善了HFD引起的心脏功能障碍.
- AGO2激活HMGCS2转录,通过β-甲酸 (β-OHB) 的过度生产将脂毒性与毒性联系起来.
- 一个PKCα-ERK-EGR1-AGO2-HMGCS2轴启动脂肪酸诱导的心肌细胞功能障碍.
结论:
- 核AGO2会加剧HFD引起的心脏功能障碍,与细胞质AGO2不同.
- 在心脏中,AGO2/HMGCS2通路连接了脂毒性和毒性.
- 这一途径代表了与代谢障碍相关的HFpEF的潜在治疗策略.
相关概念视频
01:29Heart Failure II: Pathophysiology
1.2K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.2K
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:17Pathophysiology of Heart Failure
4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
01:26Heart Failure III: Clinical Manifestations
734
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
734
01:22Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K